[Experimental models of cerebral ischemia]. 2008

R Prieto-Arribas, and A Moreno-Gutiérrez, and P Simal-Hernández, and J M Pascual-Garvi, and J Matías-Guiu, and J M Roda, and J A Barcia-Albacar
Servicio de Neurocirugía, Hospital Universitario Clínico San Carlos, E-28040 Madrid. rprieto@iib.uam.es

OBJECTIVE To provide a summary of the different experimental models of cerebral ischemia designed both under in vivo and in vitro conditions. A clear and concise description of the specific types of brain lesion reproduced by each model is given together with the most frequent technical troubles associated. METHODS Experimental models of cerebral ischemia have contributed substantially to the understanding of the physiopathology of the ischemic brain injury and to test the beneficial effects of new therapies. Outcome of patients suffering from an ischemic stroke has improved considerably with the use of these models, particularly after the introduction of thrombolytic and neuroprotective drugs. Experimental models allow the study of the evolving ischemic brain injury under strict and controlled conditions. Usefulness of experimental models is limited by their reliability, simplicity and reproducibility among different researchers. Small rodents, especially rats, have been the preferred animals used to develop models of cerebral ischemic injury, due to their cerebral physiology and vascularisation which is closer to the human. CONCLUSIONS The use of experimental models of cerebral ischemia constitutes the most suitable tool to investigate the physiopathology of this type of injury. However their simplicity prevents an exact reproduction of the cerebral damage observed in clinical settings. This could be the main reason for the discrepancies observed between the therapeutic effect in the experimental and clinical studies.

UI MeSH Term Description Entries
D012039 Regional Blood Flow The flow of BLOOD through or around an organ or region of the body. Blood Flow, Regional,Blood Flows, Regional,Flow, Regional Blood,Flows, Regional Blood,Regional Blood Flows
D002545 Brain Ischemia Localized reduction of blood flow to brain tissue due to arterial obstruction or systemic hypoperfusion. This frequently occurs in conjunction with brain hypoxia (HYPOXIA, BRAIN). Prolonged ischemia is associated with BRAIN INFARCTION. Cerebral Ischemia,Ischemic Encephalopathy,Encephalopathy, Ischemic,Ischemia, Cerebral,Brain Ischemias,Cerebral Ischemias,Ischemia, Brain,Ischemias, Cerebral,Ischemic Encephalopathies
D002560 Cerebrovascular Circulation The circulation of blood through the BLOOD VESSELS of the BRAIN. Brain Blood Flow,Regional Cerebral Blood Flow,Cerebral Blood Flow,Cerebral Circulation,Cerebral Perfusion Pressure,Circulation, Cerebrovascular,Blood Flow, Brain,Blood Flow, Cerebral,Brain Blood Flows,Cerebral Blood Flows,Cerebral Circulations,Cerebral Perfusion Pressures,Circulation, Cerebral,Flow, Brain Blood,Flow, Cerebral Blood,Perfusion Pressure, Cerebral,Pressure, Cerebral Perfusion
D004195 Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases. Animal Disease Model,Animal Disease Models,Disease Model, Animal
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D015912 Thrombolytic Therapy Use of infusions of FIBRINOLYTIC AGENTS to destroy or dissolve thrombi in blood vessels or bypass grafts. Fibrinolytic Therapy,Thrombolysis, Therapeutic,Therapeutic Thrombolysis,Therapy, Fibrinolytic,Therapy, Thrombolytic,Fibrinolytic Therapies,Therapeutic Thrombolyses,Therapies, Fibrinolytic,Therapies, Thrombolytic,Thrombolyses, Therapeutic,Thrombolytic Therapies
D018696 Neuroprotective Agents Drugs intended to prevent damage to the brain or spinal cord from ischemia, stroke, convulsions, or trauma. Some must be administered before the event, but others may be effective for some time after. They act by a variety of mechanisms, but often directly or indirectly minimize the damage produced by endogenous excitatory amino acids. Neuroprotectant,Neuroprotective Agent,Neuroprotective Drug,Neuroprotectants,Neuroprotective Drugs,Neuroprotective Effect,Neuroprotective Effects,Agent, Neuroprotective,Agents, Neuroprotective,Drug, Neuroprotective,Drugs, Neuroprotective,Effect, Neuroprotective,Effects, Neuroprotective
D020244 Infarction, Middle Cerebral Artery NECROSIS occurring in the MIDDLE CEREBRAL ARTERY distribution system which brings blood to the entire lateral aspects of each CEREBRAL HEMISPHERE. Clinical signs include impaired cognition; APHASIA; AGRAPHIA; weak and numbness in the face and arms, contralaterally or bilaterally depending on the infarction. Cerebral Infarction, Middle Cerebral Artery,Embolic Infarction, Middle Cerebral Artery,MCA Infarct,Middle Cerebral Artery Embolus,Middle Cerebral Artery Infarction,Stroke, Middle Cerebral Artery,Thrombotic Infarction, Middle Cerebral Artery,Embolus, Middle Cerebral Artery,Left Middle Cerebral Artery Infarction,MCA Infarction,Middle Cerebral Artery Circulation Infarction,Middle Cerebral Artery Embolic Infarction,Middle Cerebral Artery Occlusion,Middle Cerebral Artery Stroke,Middle Cerebral Artery Syndrome,Middle Cerebral Artery Thrombosis,Middle Cerebral Artery Thrombotic Infarction,Occlusion, Middle Cerebral Artery,Right Middle Cerebral Artery Infarction,Thrombosis, Middle Cerebral Artery,Infarct, MCA,Infarcts, MCA,MCA Infarcts

Related Publications

R Prieto-Arribas, and A Moreno-Gutiérrez, and P Simal-Hernández, and J M Pascual-Garvi, and J Matías-Guiu, and J M Roda, and J A Barcia-Albacar
January 1997, Acta anaesthesiologica Scandinavica. Supplementum,
R Prieto-Arribas, and A Moreno-Gutiérrez, and P Simal-Hernández, and J M Pascual-Garvi, and J Matías-Guiu, and J M Roda, and J A Barcia-Albacar
November 1998, Neurologia (Barcelona, Spain),
R Prieto-Arribas, and A Moreno-Gutiérrez, and P Simal-Hernández, and J M Pascual-Garvi, and J Matías-Guiu, and J M Roda, and J A Barcia-Albacar
May 2002, Ceskoslovenska fysiologie,
R Prieto-Arribas, and A Moreno-Gutiérrez, and P Simal-Hernández, and J M Pascual-Garvi, and J Matías-Guiu, and J M Roda, and J A Barcia-Albacar
January 1991, Ceskoslovenska fysiologie,
R Prieto-Arribas, and A Moreno-Gutiérrez, and P Simal-Hernández, and J M Pascual-Garvi, and J Matías-Guiu, and J M Roda, and J A Barcia-Albacar
August 2018, Reviews in the neurosciences,
R Prieto-Arribas, and A Moreno-Gutiérrez, and P Simal-Hernández, and J M Pascual-Garvi, and J Matías-Guiu, and J M Roda, and J A Barcia-Albacar
January 2002, Acta neurochirurgica. Supplement,
R Prieto-Arribas, and A Moreno-Gutiérrez, and P Simal-Hernández, and J M Pascual-Garvi, and J Matías-Guiu, and J M Roda, and J A Barcia-Albacar
January 1974, Revue d'electroencephalographie et de neurophysiologie clinique,
R Prieto-Arribas, and A Moreno-Gutiérrez, and P Simal-Hernández, and J M Pascual-Garvi, and J Matías-Guiu, and J M Roda, and J A Barcia-Albacar
April 1980, Neurosurgery,
R Prieto-Arribas, and A Moreno-Gutiérrez, and P Simal-Hernández, and J M Pascual-Garvi, and J Matías-Guiu, and J M Roda, and J A Barcia-Albacar
March 1993, Bollettino della Societa italiana di biologia sperimentale,
R Prieto-Arribas, and A Moreno-Gutiérrez, and P Simal-Hernández, and J M Pascual-Garvi, and J Matías-Guiu, and J M Roda, and J A Barcia-Albacar
February 1988, La Revue de medecine interne,
Copied contents to your clipboard!